Katherine Matthay
Professor Emeritus · University of California (San Francisco) School of Medicine
Credentials: · ·
History
Pediatrics
Research
New England Journal of Medicine · 1999 · First of 12 authors · 1,515 citations
The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report
Journal of Clinical Oncology · 2009 · 1,439 citations
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma
New England Journal of Medicine · 2010 · 1,404 citations
72 papers · 2 as a resident
- RS
64 papers
56 papers
49 papers
45 papers
43 papers
- JV
42 papers
- RH
34 papers
Grants
- 2005–2016
Biology and Therapy of High Risk Neuroblastoma
National Cancer Institute · P01
Project lead · $4.8M · Children's Hospital of Los Angeles
- 2007–2012
National Cancer Institute · P30
Project lead · $446.4K · University of California, San Francisco
- 2003–2006
131 I-MIBG Escalating Dose Rapid Sequence Double Infusi*
National Cancer Institute · R21
Contact PI · $522K · University of California, San Francisco
- 1997–2006
Pediatric Clinical Research Center
National Center for Research Resources · M01
Project lead · $1.4M · University of California, San Francisco
Clinical trials
- 2013–2021
Principal investigator · Terminated · Early phase 1
Miguel Pampaloni
- 2012–2016
Principal investigator · Completed · Phase 1
University of California, San Francisco
- 2008–2010
N2007-01: Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma
Principal investigator · Completed · Phase 2
Molecular Insight Pharmaceuticals, Inc.
- 2005–2013
Principal investigator · Completed · Phase 2
New Approaches to Neuroblastoma Therapy Consortium